- Poster presentation
- Open Access
Risk Factors for CD4 Lymphopenia in Patients Treated With a Tenofovir/Didanosine High Dose-containing Highly Active Antiretroviral Therapy Regimen
Retrovirology volume 2, Article number: P61 (2005)
In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed. Ninety-five HIV-positive patients were followed for 562 days, and 37 lost at least 50 CD4 cells, with a median delay of 274 days. Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Loungoussou, V. Risk Factors for CD4 Lymphopenia in Patients Treated With a Tenofovir/Didanosine High Dose-containing Highly Active Antiretroviral Therapy Regimen. Retrovirology 2 (Suppl 1), P61 (2005). https://doi.org/10.1186/1742-4690-2-S1-P61
- Infectious Disease
- Cancer Research
- Cell Depletion